What is Regeneron?
Regeneron operates at the intersection of advanced science and commercial medicine, specializing in the discovery, development, and manufacturing of innovative treatments for complex health conditions. The company's proprietary technology platforms have enabled significant breakthroughs in oncology, ophthalmology, and inflammatory disorders. By maintaining a rigorous focus on internal R&D, Regeneron has successfully transitioned from a research-heavy entity into a commercial powerhouse, effectively navigating the high-stakes environment of drug development to address unmet medical needs in rare and serious diseases.
How much funding has Regeneron raised?
Regeneron has raised a total of $666.1M across 3 funding rounds:
Stock Offering
$91.4M
Stock Offering
$174.7M
Debt
$400M
Stock Issuance/Offering (1991): $91.4M with participation from Undisclosed
Stock Issuance/Offering (2010): $174.7M led by Undisclosed
Debt (2011): $400M supported by Undisclosed
Key Investors in Regeneron
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Regeneron?
Looking ahead, Regeneron is positioned to leverage its substantial financial backing to further integrate artificial intelligence and high-throughput screening into its drug discovery workflows. As the company enters its next phase of enterprise-level growth, the focus will likely shift toward expanding its global manufacturing footprint and diversifying its clinical trial portfolio. By reinvesting its capital into next-generation therapeutic modalities, Regeneron aims to sustain its long-term growth trajectory while navigating the evolving regulatory and market challenges inherent in the global biotechnology industry.
See full Regeneron company page
